Inadequate reporting of research ethics review and informed consent in cluster randomized trials : review of random sample of published trials by Taljaard, Monica et al.
RESEARCH
Inadequate reportingof researchethics reviewand informed
consent in cluster randomised trials: review of random
sample of published trials
Monica Taljaard, scientist,1 Andrew D McRae, research director,2 Charles Weijer, professor,3 Carol Bennett,
research coordinator,1 Stephanie Dixon, postdoctoral fellow,4 Julia Taleban, PhD candidate,4 Zoe Skea,
research fellow,5 Martin P Eccles, professor,6 Jamie C Brehaut, scientist,1 Allan Donner, professor,4 Raphael
Saginur, professor,7 Robert F Boruch, professor,8 Jeremy M Grimshaw, senior scientist1
ABSTRACT
Objectives To investigate the extent to which authors of
cluster randomised trials adhered to two basic
requirements of the World Medical Association’s
Declaration of Helsinki and the International Committee
of Medical Journal Editors’ uniform requirements for
manuscripts (namely, reporting of research ethics review
and informed consent), to determine whether the
adequacy of reporting has improved over time, and to
identify characteristics of cluster randomised trials
associated with reporting of ethics practices.
Design Review of a random sample of published cluster
randomised trials from an electronic search in Medline.
Setting Cluster randomised trials in health research
published in English language journals from 2000 to
2008.
Study sample 300 cluster randomised trials published in
150 journals.
Results 77 (26%, 95% confidence interval 21% to 31%)
trials failed to report ethics review. The proportion
reporting ethics review increased significantly over time
(P<0.001). Trials with data collection interventions at the
individual level were more likely to report ethics review
than were trials that used routine data sources only (79%
(n=151) v 55% (23); P=0.008). Trials that accounted for
clustering in the design and analysis were more likely to
report ethics review. The median impact factor of the
journal of publication was higher for trials that reported
ethics review (3.4 v 2.3; P<0.001). 93 (31%, 26% to 36%)
trials failed to report consent. Reporting of consent
increased significantly over time (P<0.001). Trials with
interventions targeting participants at the individual level
were more likely to report consent than were trials with
interventions targeting the cluster level (87% (90) v 48%
(41); P<0.001). Trials with data collection interventions at
the individual level were more likely to report consent
thanwere those that used routine data sources only (78%
(146) v 29% (11); P<0.001).
Conclusions Reporting of research ethics protections in
cluster randomised trials is inadequate. In addition to
research ethics approval, authors should report whether
informed consent was sought, from whom consent was
sought, and what consent was for.
INTRODUCTION
Cluster randomised trials are distinct from other ran-
domised controlled trials in that the units of random
assignment are intact clusters of entities such as entire
medical practices, hospitals, schools, or communities,
rather than the constituent individuals of these units
themselves.1 The statistical implications of this hier-
archical structure arewell recognised, and an extensive
literature exists to provide guidance for the appropri-
ate design and analysis of these trials, but relatively
little attention has been paid to the ethical
implications.2-5Obtaining informed consent, for exam-
ple, is more complicated in cluster randomised trials,
not only because groups of participants need to be ran-
domised as a whole (often before identification of eli-
gible participants within clusters) but also because the
experimental treatment may need to be delivered to
the cluster as a whole. The experimental treatment
may be a medical therapy, health promotion cam-
paign, or public health intervention targeting indivi-
dual members of a cluster, or it may be an
educational intervention targeting a health profes-
sional or a quality improvement intervention targeting
the cluster organisation. Moreover, a “gatekeeper” or
someone who is authorised to consent on behalf of a
cluster without necessarily receiving the intervention
him/herself may exist (for example, a school principal
or the chief executive at a hospital). Furthermore, out-
comes of interest may need to be collected from parti-
cipants at the level of the individual (such as patients,
students, or employees), the cluster (such as health pro-
fessionals, school teachers, or shift supervisors), or
both, or they may be available from routine data
sources within each cluster (for example, patients’
medical records, health insurance records). Althabe
et al, for example, randomised 19 hospitals to receive
a multifaceted behavioural intervention to promote
implementation of evidence based obstetrical
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practices.6 The unit of randomisation was the hospital,
the intervention was targeted at birth attendants in
each hospital, and outcomes were observed in indivi-
dual patients. In this trial, responsible authorities at
each hospital, as well as birth attendants, provided
written consent to participate in the trial; no consent
was sought from patients, as outcomes were part of
routine data collected at each hospital with no personal
identifying information transmitted.
We report here one component of a project to study
ethical challenges in health related cluster randomised
trials.7 An in-depth analysis of the ethical challenges,
together with preferred solutions, is presented
elsewhere8; here, we focus on the practice of the report-
ing of two key pieces of information relevant to a vari-
ety of these ethical requirements—namely, approval
by a research ethics committee and informed consent.
According to the World Medical Association’s
Declaration of Helsinki, research studies should be
approved by an independent research ethics commit-
tee and, when appropriate, informed consent should
be sought from study participants.9 Likewise, the UK
MedicalResearchCouncil’s guidelines for the conduct
of cluster randomised trials require ethics review and
voluntary informed consent from participants, where
possible.10 The International Committee of Medical
Journal Editors’ (ICMJE’s) uniform requirements for
manuscripts submitted to biomedical journals requires
that: “authors should indicate whether the procedures
followedwere in accordance with the ethical standards
of the responsible committee on human experimenta-
tion (institutional and national) and with the Helsinki
Declaration. . . If doubt exists whether the researchwas
conducted in accordance with the Helsinki Declara-
tion, the authors must explain the rationale for their
approach and demonstrate that the institutional review
body explicitly approved the doubtful aspects of the
study.”11 Close to 900 journals now state that they
have adopted the ICMJE’s requirements.
The minimum requirements of clear reporting of
ethics practices apply equally in cluster randomised
trials. Donner and Klar proposed that: “As a first step
in developing a well-accepted set of ethical principles
and norms for cluster randomization trials, editors
could require all articles describing results to report
having institutional review board approval.” They
also recommend that: “When permission from key
decision-makers associated with each cluster is needed
for assigning interventions, some indication should be
provided as to who these decision-makers are and how
they were identified. Some information about the con-
sent procedure administered to individual study parti-
cipants should also be provided.”5
This study aimed to review the adequacy of report-
ing of these minimum ethical criteria in cluster rando-
mised trials. On the basis of a representative sample of
published cluster randomised trials, our primary
objectives were to investigate the frequency of report-
ing of research ethics review and informed consent in
cluster randomised trials in health research, investigate
whether the rate of reporting has increased over time,
and identify methodological characteristics associated
with reporting these basic ethical requirements.
METHODS
Search strategy and article selection
Weused an electronic search strategy (box) with a sen-
sitivity of 90.1% and a precision of 18.4% to identify
reports of cluster randomised trials in health research,
published in English language journals between 2000
and 2008.12 We implemented the search strategy on 4
December 2008 in the Ovid Medline database from
1996 to the third week of November 2008. We
assigned a computer generated uniform random num-
ber to each identified report.We sorted reports by ran-
dom number and screened titles and abstracts of
reports (as well as full text where necessary) to identify
trials that met our eligibility criteria. For calibration
purposes, two reviewers (MT and CB) initially
screened a training sample of 300 records. They dis-
cussed disagreements and calculated the κ statistic to
assess agreement in the identification of trials. If the κ
statistic did not reach 0.85, both reviewers screened the
next 300 records until the κ statistic reached at least
0.85. Thereafter, reviewers screened records sepa-
rately until the target sample size of 300 eligible cluster
randomised trials was reached. We used the sample
size of 300 trials to restrict the width of a 95% two
sided confidence interval around the estimated pro-
portion of trials reporting research ethics review or
informed consent. The maximum width of 11.4% is
obtained by using the most conservative estimate of
observed proportion equal to 50%.
Inclusion and exclusion criteria
We included an article if it was the main report of a
cluster randomised trial. We excluded pilot studies,
Medline search strategy to identify cluster randomised trials (sensitivity=90.1%,
precision=18.4%)
1. randomized controlled trial.pt.
2. animals/
3. humans/
4. 2 NOT (2 AND 3)
5. 1 NOT 4
6. cluster$ adj2 randomi$.tw.
7. ((communit$ adj2 intervention$) OR (communit$ adj2 randomi$)).tw.
8. group$ randomi$.tw.
9. 6 OR 7 OR 8
10. intervention?.tw.
11. cluster analysis/
12. health promotion/
13. program evaluation/
14. health education/
15. 10 OR 11 OR 12 OR 13 OR 14
16. 9 OR 15
17. 16 AND 5
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trial protocols, trials randomising households or dyads
of different individuals, short communications or con-
ference proceedings, trials with further allocation of
individuals within clusters, quasi-randomised designs,
secondary analyses of trials, and trials reporting only
baseline findings.
Data abstraction
We developed data abstraction forms, pilot tested
them, and then applied them to a sample of 21 cluster
randomised trials for calibration of reviewers. All six
reviewers (MT,ADMcR,CB, SD, JT, andZS) indepen-
dently abstracted these 21 trials. We identified differ-
ences and resolved them by discussion. Rotating pairs
of reviewers then independently abstracted the remain-
der of the trials. After each set of 20 trials had been
abstracted, discrepancies were reviewed within the
pair and resolved by consensus. If differences could
not be resolved, one reviewer (MT) was the arbitrator.
We abstracted information about ethics review pro-
cedures for the trials: whether or not approval was
reported, whether the ethics committees were identi-
fied in the report, and, if so, how many committees
were involved. If an author reported that a trial was
exempt from ethics review, we recorded the reason
for the exemption, if explained. We further extracted
information about any informed consent procedures
reported, distinguishing between consent from partici-
pants at the level of the cluster and the individual. We
also recorded any other statements of consent—for
example, from someone who could be considered a
gatekeeper. If an author reported that a waiver of con-
sent had been obtained from the research ethics com-
mittee, we recorded the reason for the waiver, if
explained.
The data abstraction instrument also collected items
on year of publication, country of study recruitment,
type of cluster being randomised, number and size of
clusters randomised, and study design and analysis.
For each trial, we recorded whether any experimental
interventions targeted participants at the individual
level and at the cluster level. We also recorded the
type of data collection activities that were used, speci-
fied as the use of routinely available data (such as
administrative or medical records) or the use of any
direct intervention on or interaction with participants
for purposes of data collection, including physical
examination, medical tests, or interactions such as sur-
veys or interviews at both the individual level and the
cluster level.
Analysis
We summarised results by using frequencies and per-
centages for categorical variables and medians and
interquartile ranges for continuous or ordinal vari-
ables; we used asymptotic or exact methods to calcu-
late 95% confidence intervals for proportions where
appropriate. To test the significance of changes over
time, we used the Cochran-Armitage test for trend.
We tested associations between the reporting of ethical
practices and characteristics of trials by using Pearson
χ2 tests for categorical variables and Wilcoxon two
sample tests for continuous variables. Characteristics
of trials investigated included the level(s) at which
interventions were offered, categorised as cluster
level only, individual level only, or both individual
and cluster level, as well as the types of data collection
activities that were used, categorised as the use of
Table 1 | Characteristics of cluster randomised trials included
in review. Values are numbers (percentages) unless stated
otherwise
Characteristic Value (n=300)
Publication year:
2000-1 44 (15)
2002-3 49 (16)
2004-5 87 (29)
2006-7 99 (33)
2008 21 (7)
Journal impact factor (n=294):
Median (interquartile range) 2.9 (2.1-5.1)
Range 0.45-50.0
Country of study recruitment:
United States 114 (38)
UK or Ireland 50 (17)
Canada 16 (5)
Australia or New Zealand 16 (5)
Other 104 (35)
Country’s level of development:
Advanced economies 255 (85)
Emerging and developing economies 45 (15)
Healthcare organisation or setting:
Medical practices or clinics 81 (27)
Individual health professionals 41 (14)
Hospitals, hospital units, hospital wards 25 (8)
Nursing homes or wards 16 (5)
Residential areas (such as postal codes of
family practices)
6 (2)
Non-healthcare organisation or setting:
Schools or classrooms 66 (22)
Residential areas (such as villages, districts,
housing units)
39 (13)
Worksites 16 (5)
Sports teams, clubs, churches, other social
groups
10 (3)
No of clusters randomised (n=285):
Median (interquartile range) 21.0 (12-52)
Range 2-605
Average cluster size (n=271):
Median (interquartile range) 33.9 (12.5-88.5)
Range 1.7-122 855
Target of interventions:
Cluster level only 99 (33)
Individual level only 105 (35)
Both cluster level and individual level 96 (32)
Types of data collection interventions:
Individual level only 192 (64)
Cluster level only 23 (8)
Both individual level and cluster level 40 (13)
Routine data only 45 (15)
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routinely available data only or data collection inter-
ventions administered to participants at the cluster
level, the individual level, or both. We also investi-
gated associations with the country where the study
tookplace, aswell as its level of development, classified
as advanced economies versus emerging and develop-
ing economies according to the October 2008 edition
of the world economic outlook database.13 We investi-
gated associations with cluster type by grouping
together trials in which the unit of randomisation or
intervention was a healthcare provider or healthcare
organisation, such as a primary care practice, hospital
ward, or nursing home, and comparing themwith trials
involving non-healthcare organisations such as
schools, worksites, or residential areas.
To investigate associations withmethodological and
reporting quality of trials, we classified each trial on the
basis ofwhether twokeymethodological and reporting
requirements for cluster randomised trials were met—
namely, accounting for clustering during sample size
calculation and accounting for clustering during analy-
sis, as stipulated by the CONSORT statement exten-
sion to cluster randomised trials.14 Trials that fail to
account for clustering in the design risk underestimat-
ing sample size requirements, and trials that fail to
account for clustering in the analysis risk overstating
the statistical significance of the findings.1We classified
a trial as meeting the sample size requirement if the
sample size calculation was presented and clearly
accounted for clustering (for example, by using the
intracluster correlation coefficient, coefficient of varia-
tion, or cluster level summary statistics), and we classi-
fied a trial as meeting the analysis requirement if the
method of analysis was reported and was clearly
appropriate for the clustered design (for example,
adjustment for the intracluster correlation coefficient,
use of a mixed effects regression analysis, or use of
cluster level summary statistics). We also investigated
associations with journal impact factor, obtained from
journal citation reports (ISIWeb of Science, 2009). For
journals with no ranking available, we used the journal
impact ranking of the open access SMImago journal
and country rank database, if available.15 The SMI-
mago journal and country rank is calculated with a
similar formula and is very strongly correlated with
the journal citation report ranking.16 We used SAS
v.9.1 for all analyses, with a level of significance set at
α=0.01. We selected a stringent level of significance
because we were doing multiple tests of association.
RESULTS
We identified close to 17 000 articles with the search
strategy (figure). We reached the target sample size of
300 eligible cluster randomised trials after screening a
random sample of 4155 records. Identification of trials
as cluster randomised trials in titles or abstracts was
poor, and in a large number of cases we had to down-
load the full article to confirm whether it was a cluster
randomised trial. The κ statistic for agreement on
inclusion of studies was 0.87 after three rounds of
screening (the κ statistics in the first two rounds were
0.75 and 0.83).
Table 1 shows the characteristics of the 300 trials
included in the review. We included trials from 150
different journals (listed in web appendix). Four fifths
of the studies were dispersed among 146 different jour-
nals, whereas four journals included approximately
one fifth of the trials: BMJ (22 trials), JAMA (12 trials),
Lancet (11 trials), and Preventive Medicine (11 trials).
Slightly more than two thirds of reports in our sample
were published during or after 2004, suggesting an
increase in the use of cluster randomisation over
time. The types of clusters randomised were diverse
and includedmedical practices, nursing homes, indivi-
dual health professionals, residential areas, schools,
worksites, and social units such as sports teams,
churches, or civic clubs.
Trials represented diverse types of interventions: the
target of the intervention was exclusively at the indivi-
Table 2 | Reporting of research ethics review in cluster
randomised trials. Values are numbers (percentages) unless
stated otherwise
Value (n=300)
95% confidence
interval of %
Research ethics review reported?
Yes 218 (73) 68 to 78
No 77 (26) 21 to 31
Exempt from review 5 (2) 0.5 to 4
If ethics review reported, were committees identified?
Yes 191 (88) 83 to 92
No 27 (12) 8 to17
No of committees, if identified (n=191)
Median (interquartile
range)
1 (1-2) NA
Range 1-38 NA
If exempt from review, was reason given?
Yes 2 NA
No 3 NA
NA=not applicable.
Records identified by Medline search (n=16 997)
Randomly selected (n=4155)
Identified as possibly eligible CRTs (n=440)Excluded as non-CRTs or clearly ineligible (n=3715)
Did not meet eligibility criteria (n=161):
  Secondary analysis of trials (n=70)
  Trial protocol only (n=30)
  No outcomes at individual level (n=20)
  Quasi-randomised design (n=16)
  Households or families as units of
    randomisation (n=12)
  Pilot study (n=7)
  Further allocation of individuals within clusters
    (n=6)
Met eligibility criteria (n=279)
Trials included in review (n=300)
Trials from pilot testing
phase included (n=21)
Not selected (n=12 842)
Identification of sample of 300 cluster randomised trials (CRTs) included in review
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dual level in approximately one third of trials, exclu-
sively at the cluster level in another third, and at both
levels in the remaining third. In most trials (64%), data
collection interventions were targeted solely at the
individual level; 13% included data collection inter-
ventions targeted at participants at both individual
and cluster levels, and 8% collected data exclusively
from participants at the level of the cluster. Fifteen
per cent had data collection interventions at neither
individual nor cluster level, using routinely available
data only.
Table 2 shows details of the reporting of research
ethics review: 26% (95% confidence interval 21% to
31%) of trials failed to report ethics approval, and
73% (68% to 78%) of trials reported that one or more
research ethics committees had reviewed the study.
Among the five trials that reported exemption from
ethics review, only two gave explicit reasons for the
exemption, both relating to the trials being quality
improvement initiatives: “With the primary focus of
the project being process quality improvement, none
of the mammography centers deemed it necessary to
submit the project through its institutional review
board process” and “An application for ethical
approval was submitted to the [name deleted]
Research Ethics Committee. We were informed that
the study should be regarded as auditing the effects of
change in the hospital’s services and research ethics
approval was not required for this.” Among trials that
identified ethics approval, 88% named the ethics com-
mittee(s) involved.
Table 3 presents the results of our analyses investi-
gating characteristics associated with the reporting of
ethics review. We excluded the trials that reported
exemption from ethics review for the purpose of
doing tests of association, as the number of trials in
this category was very small (n=5). The frequency of
reporting of research ethics review increased strongly
over time: in 2000-1, slightly more than half of trials
reported ethics approval; this increased to 82%of trials
published in 2006-7 and 95% of trials published in
2008 (test for trend, P<0.001).We foundno statistically
significant differences according to the country in
which the study took place or its level of economic
development. Reporting of research ethics approval
did not vary significantly by type of randomisation
unit or target of planned interventions but was signifi-
cantly associatedwith the types of data collection inter-
ventions (P=0.008). Specifically, the empirical estimate
of the propensity to report ethics approval for trials
using routine data only was 55% compared with 79%
when data collection was exclusively at the individual
level. We found a significant association between
reporting of ethics approval and indicators of metho-
dological quality: trials with clearly reported sample
size calculations (P<0.001) and analyses accounting
for clustering (P=0.006) were more likely to report
ethics approval. Moreover, the median journal impact
factor among trials that reported ethics approval was
higher than among those that did not report this
approval (P<0.001).
Table 4 shows details of informed consent proce-
dures reported. Among the 300 trials included in our
review, 64% (58% to 69%) reported on consent,
whereas 31% (26% to 36%) failed to report any consent.
Among the trials that reported consent, 17% reported
on consent from more than one type of participant—
for example, gatekeeper or participant at cluster level
or individual level. Among all 300 trials, 5% reported
consent from gatekeepers, 11% reported consent from
cluster level participants, and 59% reported consent
from individual level participants. Among 16 trials
that reported a waiver of consent, only five provided
a reason for the waiver: “Outcome data were routinely
collected at hospitals and no personal identifiers were
transmitted;” “Due to the design of the study, it was not
possible to obtain informed consent from the
Table 3 | Characteristics associated with reporting of research ethics review in cluster
randomised trials. Values are numbers (row percentages) unless stated otherwise
Characteristic
Ethics review
reported (n=218)
Ethics review not
reported (n=77) P value
Year of publication:
<0.001
2000-1 23 (52) 21 (48)
2002-3 34 (69) 15 (31)
2004-5 61 (73) 23 (27)
2006-7 80 (82) 17 (18)
2008 20 (95) 1 (5)
Country of study recruitment:
0.623
United States 84 (74) 29 (26)
UK or Ireland 37 (76) 12 (24)
Canada 14 (88) 2 (13)
Australia or New Zealand 11 (79) 3 (21)
Other 72 (70) 31 (30)
Country’s level of development:
0.080Advanced economies 180 (72) 70 (28)
Emerging and developing economies 38 (84) 7 (16)
Unit of randomisation:
0.031Healthcare organisation 130 (79) 35 (21)
Non-healthcare organisation 88 (68) 42 (32)
Target of interventions:
0.668
Cluster level only 68 (72) 27 (28)
Individual level only 80 (77) 24 (23)
Both cluster level and individual level 70 (73) 26 (27)
Types of data collection interventions:
0.008
Individual level only 151 (79) 40 (21)
Cluster level only 14 (64) 8 (36)
Both individual level and cluster level 30 (75) 10 (25)
Routine data only 23 (55) 19 (45)
Sample size calculation accounted for intracluster
correlation coefficient:
<0.001Yes 85 (87) 13 (13)
No 133 (68) 64 (32)
Analysis accounted for intracluster correlation
coefficient:
0.006Yes 161 (79) 44 (21)
No 57 (63) 33 (37)
Median (interquartile range) journal impact factor
(n=289)
3.4 (2.2-7.3) 2.3 (1.7-3.6) <0.001
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participants in the trial;” “Data were collected . . . as
part of the hospital’s quality improvement activities
and did not require informed consent from the
patients;” “The intervention was a policy change at
the hospital level, control hospitals were not to change
their usual practices, and no individual data was to be
collected;” and “Consent was not sought because this
study was a pragmatic implementation of health-ser-
vice provision strategies.”
Table 5 shows the results of our analyses investigat-
ing characteristics associatedwith the reporting of con-
sent. We excluded trials that reported waivers of
consent for the purpose of doing tests of association,
as the number of trials in this category was small
(n=16). We found a strong increase over time in the
reporting of consent, from only 36% of trials in 2000-
1 reporting any consent to 80% of trials in 2006-7 and
95% of trials in 2008 (test for trend, P<0.001). Report-
ing of consent did not vary significantly by country,
level of economic development, or type of cluster.
Reporting of consent was significantly associated with
the target of planned interventions (P<0.001): the
empirical estimate of the propensity to report consent
for trials with interventions targeting individuals only
was 87% compared with 48% for trials with inter-
ventions targeted solely at the cluster level. Reporting
of consent was also significantly associated with types
of data collection interventions (P<0.001): the empiri-
cal estimate of the propensity to report consent for
trials collecting routine data only was 29% compared
with 78% and 40% for trials with data collection inter-
ventions solely at the individual level or the cluster
level.We found no significant associationswith indica-
tors of methodological quality, although we found a
trend towards a significant association with journal
impact factor (P=0.010).
DISCUSSION
Among 300 cluster randomised trials published
between 2000 to 2008 in 150 different journals, 26%
lacked a statement of ethics approval and 31% failed
to report informed consent, but we found evidence of
improvement over time. Trials with interventions and
data collection activities targeted at the individual
level, as well as trials that adhered to important meth-
odological recommendations for cluster randomised
trials and those reported in higher impact factor jour-
nals, were more likely to report on these basic ethical
requirements.
Strengths and limitations of study
This is the first study to use a large sample of reports
from a wide range of journals in health research to for-
mally investigate reporting of ethics practices in cluster
randomised trials. As our search strategy had a sensi-
tivity of 90%, we expect our random sample to be
representative of most cluster randomised trials in
health research published in Medline between 2000
and 2008; however, approximately 10% of cluster ran-
domised trials would not have been identified by our
search strategy. Moreover, we cannot completely rule
out selection bias in the identification of published
reports from the search strategy. Identification of trials
as cluster randomised in published reports was poor—
only 48.3% of trials were clearly identified, in contra-
vention of the CONSORT recommendation that trials
should be clearly identified as “cluster randomised” in
titles or abstracts. To reduce the risk of selection bias,
we downloaded the full article, where necessary, to
definitively rule out cluster randomisation and pro-
ceeded with screening only after two reviewers
reached satisfactory agreement in the identification of
trials. Nevertheless, some poorly reported trials could
have beenmissed during the screeningprocess. If these
trials were also less likely to report on ethical require-
ments, our results could have overestimated the pro-
portions of trials reporting ethical requirements. To
reduce the risk of misclassification of ethics reporting
practices and trials’ characteristics, we used a consen-
sus between two reviewers who independently extra-
cted information about ethical and methodological
factors from the published reports.
Comparison with other studies
The proportion of cluster randomised trials failing to
report on ethical requirements seems to be higher than
innon-cluster randomised trials. For example, a review
of 259 phase 3 trials of cancer treatments published
between 1999 and 2001 in 10 international journals
found that 33% failed to report ethics review and 9%
Table 4 | Reporting of informed consent procedures in cluster
randomised trials (n=300)
Frequency (%) 95%confidence interval of%
Any consent reported?
Yes 191 (64) 58 to 69
No 93 (31) 26 to 36
Waiver of consent 16 (5) 3 to 8
Levels of consent, if reported
Multiple levels 33 (17) 12 to 23
Single level 158 (83) 77 to 88
Any consent reported from gatekeeper?
Yes 15 (5) 3 to 8
No 285 (95) 93 to 98
Any consent reported from participants at cluster level?
Yes 34 (11) 8 to 15
No 266 (88) 85 to 92
Any consent reported from participants at individual level?
Yes 178 (59) 54 to 65
No 122 (41) 35 to 47
If waiver of consent reported, was justification given?
No 11 (69) 41 to 89
Yes 5 (31) 11 to 59
In statement of consent at cluster level, was method reported?
Yes 18 (53) 35 to 70
No 16 (47) 30 to 65
In statement of consent at individual level, was method reported?
Yes 123 (69) 62 to 76
No 55 (31) 24 to 38
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failed to report informed consent17; the corresponding
proportions of cluster randomised trials between 2000
and 2001 in our review were 48% and 64%. Another
review of all 1133 clinical research articles published
between 2005 and 2006 in four major clinical journals
found that 3.2% lacked a statement of ethics approval
and 5.5% lacked a statement of informed consent18;
over the corresponding time period in our review, the
proportions were 26% and 24%. Although higher pro-
portions may be expected given the broader sample of
journals included in our review, this is unlikely to be
the sole explanation for this discrepancy.
Several possible explanations exist for incomplete
reporting of ethics practices in cluster randomised
trials.One explanation is uncertainty among investiga-
tors about the need to seek research ethics approval
and informed consent in different types of cluster
randomised trials. A second explanation is that ethics
approval or informed consent was in fact not needed
(but the authors did not consider this an important
detail to report, and journals did not explicitly require
waivers to be reported). Despite the ICMJE’s recom-
mendations, considerable variability remains in
requirements by different journals: some require that
ethics approval is stated in the methods section of the
manuscript, whereas others require only a separate
signed statement from the author; others simply state
that studies must have ethics approval but do not men-
tion a method of documentation.19 Yet another possi-
bility is misclassification by reviewers, due to poor
reporting of consent practices in the trial report (for
example, informed consent may have been sought
but the authors simply reported that participants
“agreed to participate” without an explicit statement
of consent). To classify a trial as reporting consent,
we required a clear statement of consent in the pub-
lished report. We were guided by the basic compo-
nents of informed consent as stated by the
Declaration of Helsinki, including that the participants
must be adequately informed about the research
study’s aims, procedures, potential benefits, and risks
and the fact that participation is voluntary.9 We found
an indication that authors used more rigorous stan-
dards when reporting consent practices at the indivi-
dual level than at the cluster level: 69% of trials that
reported consent at the individual level reported
whether the method was written or verbal, but only
53% of trials that reported consent at the cluster level
provided such details. Authors may, therefore, have
considered a statement of “agreement” as adequate
when describing consent practices from health profes-
sionals or other participants at the cluster level but used
more conventional descriptors when reporting con-
sent practices at the level of the individual patient.
Other reviews of ethics reporting practices have
found that failure to disclose ethics approval or
informed consent is significantly associated with indi-
cators of lower methodological and reporting
quality.17 20 Here, we found a significant association
between reporting of research ethics review and two
key indicators ofmethodological and reporting quality
in cluster randomised trials—namely, accounting for
clustering in sample size calculations and analyses.
Trials that adhered to more rigorous methodological
and reporting standards were more likely to report
ethics approval. We also found that articles published
in journals with higher impact factors weremore likely
to disclose ethics approval, although we recognise that
the impact factor may be an imperfect surrogate for
methodological and reporting quality.
Other authors have shown empirically that charac-
teristics of the interventions in cluster randomised
trials are associated with consent practices.21 22 For
example, in a review of 152 published cluster rando-
mised trials carried out in primary care settings
between 1997 and 2000, Eldridge et al found that the
proportions that obtained patients’ consent varied
between 31% and 80%, depending on the kinds of
Table 5 | Characteristics associated with reporting of any informed consent procedures in
cluster randomised trials. Values are numbers (row percentages) unless stated otherwise
Characteristic
Consent reported
(n=191)
Consent not reported
(n=93) P value
Year of publication:
<0.001
2000-1 15 (36) 27 (64)
2002-3 28 (57) 21 (43)
2004-5 56 (69) 25 (31)
2006-7 74 (80) 19 (20)
2008 18 (95) 1 (5)
Country of study recruitment:
0.365
United States 70 (65) 38 (35)
UK or Ireland 33 (67) 16 (33)
Canada 14 (88) 2 (13)
Australia or New Zealand 11 (79) 3 (21)
Other 63 (65) 34 (35)
Country’s level of development:
0.383Advanced economies 161 (66) 82 (34)
Emerging and developing economies 30 (73) 11 (27)
Unit of randomisation:
0.036Healthcare organisation 98 (62) 60 (38)
Non-healthcare organisation 93 (74) 33 (26)
Target of planned interventions:
<0.001
Cluster level only 41 (48) 45 (52)
Individual level only 90 (87) 14 (13)
Both cluster level and individual level 60 (64) 34 (36)
Types of data collection interventions:
<0.001
Individual level only 146 (78) 42 (22)
Cluster level only 8 (40) 12 (60)
Both individual level and cluster level 26 (69) 12 (32)
Routine data only 11 (29) 27 (71)
Sample size calculation accounted for intracluster
correlation coefficient:
0.142Yes 68 (73) 25 (27)
No 123 (64) 68 (36)
Analysis accounted for intracluster correlation
coefficient:
0.253Yes 136 (69) 60 (31)
No 55 (63) 33 (38)
Median (interquartile range) journal impact factor
(n=278)
3.1 (2.2-5.1) 2.6 (1.8-4.8) 0.010
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interventions under study.21 Although these authors
foundno evidence that consent practices have changed
over time, our results show that the frequencies of
reporting research ethics approval and informed con-
sent have increased significantly over time. This may
be in response to a small number of publications that
have started discussing ethical challenges in cluster
randomised trials, such as the UK Medical Research
Council’s guidelines for cluster randomised trials, pub-
lished in November 2002, which included a section on
ethical factors.10 Itmay also be an indirect result of gen-
eral increased awareness of the importance of report-
ing quality brought about by publication of the
CONSORT statement and its extension to cluster ran-
domised trials.14
Conclusions and policy implications
Cluster randomised trials are challenging to do and
report, not only because they usually involve complex
interventions but also because no explicit guidelines
with international reach exist to answer basic questions
such as from whom, when, and how informed consent
ought to be sought.8 In the same trial, different compo-
nents of an intervention may be targeted at multiple
kinds of participants, and each kind of participant
may need to be approached for informed consent.
Moreover, consent may involve consent to be rando-
mised, to receive an intervention, or simply to provide
data. We have focused here on the reporting of ethics
review and informed consent in cluster randomised
trials. Whether current practices are satisfactory in
respecting the interests of individual participants in
trials depends on the findings of further normative
reflection. Conceptual work is needed to determine
under what circumstances participants in cluster ran-
domised trials need to be considered research subjects,
and then under what circumstances consent for parti-
cipation is needed.8 Greater clarity in the reporting of
ethics practices in cluster randomised trials is an impor-
tant first step in reinforcing good practices in trial con-
duct and ethics review, for remediation of errors in
consent practices and ethics review, and for the
development of regulatory guidance for cluster rando-
mised trials. As a minimum, we recommend that
authors report the following. (1) Whether research
ethics approval was obtained; if ethics review was not
required, a reason should be given in the report. (2)
Whether informed consent was sought; if a waiver of
consent was obtained, this should be stated, together
with a reason for the waiver. (3) From whom consent
was sought and what consent was for—for example,
randomisation, intervention, or data collection.
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